Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:11.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a clinical trial evaluating the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer expressing high levels of PD-L1.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:54.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value for Participation Criteria has been updated to provide a detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. The new description also includes specific inclusion and exclusion criteria for participants with stage IV NSCLC.
    Difference
    14%
    Check dated 2024-05-22T21:12:46.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:29:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.